Dan Smith

Planview and Ozmosi: Bringing AI-Powered Insight to Pharmaceutical Portfolio Decisions

by

Pharmaceutical organizations are under increasing pressure to make faster, smarter R&D decisions in an environment defined by complexity, uncertainty, and constant change. Making the environment even more vulnerable – and volatile – is the looming “patent cliff” for some of the world’s best-selling drugs, which some analysts predict will trigger up to $350 billion in losses by 2032, according to CNBC.

Using Data Analytics to Navigate Tariff Impacts on Your Product Portfolio

by

Some uncertainty is inevitable for product-driven organizations. To mitigate risk and maximize value, most organizations perform a comprehensive impact analysis before making any investment decisions. However, some impacts are easier to estimate than others. Microeconomic industry changes, such as demand fluctuations or predictable innovations, are relatively straightforward – for example, automotive organizations can anticipate electric…